ClinicalTrials.gg
RecruitingNCT05481619Updated Jul 25, 2025

Study of the Effect of Vedolizumab on Intestinal Microecological Changes and Its Efficacy in the Treatment of Ulcerative Colitis

A Phase 4 interventional study of Vedolizumab in Ulcerative Colitis, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University. Recruiting at 1 site in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-25.

Sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2026, 10 months ago, but the record still lists the study as recruiting.
  • Registered 1 year 6 months after the study started (first participant enrolled Jan 2021, registered Jul 2022).
  • Started Jan 2021; still recruiting 5 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 38 studies testing vedolizumab in Colitis, Ulcerative — 5 open to participants now, 9 under way, 6 of them phase 3. vedolizumab · Colitis, Ulcerative.

Planned enrollment
30th of 38
30 · median 110
Started
2021
with 4 others
Phase 4
15 of 38
2 open now
Registered
31st of 38
by date

Among the 38 studies testing vedolizumab in Colitis, Ulcerative, this one is the 30th largest by planned enrollment, is one of 5 that started in 2021, is one of 15 in phase 4, and was the 31st registered.

Colitis, Ulcerative

1,857 studies on the registry are indexed under Colitis, Ulcerative; 472 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

5 of the 38 studies testing vedolizumab in Colitis, Ulcerative are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About vedolizumab

vedolizumab: first FDA approval 2014 (ENTYVIO), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 305 Colitis, Ulcerative studies recruiting now, 135 (44%) set no upper age limit and 134 (44%) stop at 75 or younger; 70 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing vedolizumab in Colitis, Ulcerative, or all of them as a file.
02

Study summary

Inflammatory bowel disease is a group of chronic, non-specific inflammatory diseases of the intestinal tract whose etiology has not yet been fully elucidated, including ulcerative colitis and Crohn's disease. Vedolizumab, a novel biologic agent, is a recombinant humanized monoclonal antibody that specifically antagonizes intestine-selective α4β7 integrins on the surface of leukocyte subsets, thereby preventing migration of leukocyte subsets from the blood to the intestinal mucosa and reducing local inflammation in the gut. In this study the investigators propose to build on an existing cohort and analyse, by means of a multi-omics approach, the baseline gut microbial composition and abundance, intestinal and serum metabolome characteristics of UC patients and their changes during treatment, to predict the functional mechanisms by which these changing characteristics influence the therapeutic response to vindolizumab.

Read the detailed description

Stool and blood samples etc. were taken from a cohort of patients with ulcerative colitis treated with Vedolizum at the Department of Gastroenterology, Second Affiliated Hospital of Zhejiang University School of Medicine as well as from a cohort of normal volunteers. Stool and blood samples from UC patients were analyzed at baseline and at 14, 30, and 52 weeks after starting treatment. Analysis of changes in gut microbial composition and abundance, gut and serum metabolome characteristics during 52 weeks of treatment in patients with UC. A model for predicting the efficacy of vedolizumab treatment by baseline gut microbial composition and abundance, and gut and serum metabolomic characteristics in patients with ulcerative colitis was developed in conjunction with clinical information from patients in the cohort. Based on the model developed, clinical and gut microbial composition and abundance, gut and serum metabolomics data from other UC patients published in public databases were combined to confirm the results already found using the UC cohort at our center.

03

Conditions studied

  • Ulcerative Colitis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 years of age or older, with moderate to severe ulcerative colitis, with an indication for vedolizumab treatment;
  2. Consent to participate in the study, read and sign the form;
  3. No previous treatment with vedolizumab;
  4. Never undergone biologic therapy or at least suspended previous biologic therapy for more than 12 weeks;
  5. Not taking antibiotics or probiotics within the past 4 weeks.

Exclusion criteria

Exclusion Criteria:

  1. younger than 18 years of age;
  2. pregnant or breastfeeding women;
  3. patients who require the assistance of a surrogate, witness, or who are otherwise unable to complete the trial unaided;
  4. other conditions that, in the opinion of the investigator, are unsuitable for enrollment or affect the subject's ability to complete the study;
  5. have taken antibiotics or probiotics within the past 4 weeks;
  6. have received prior treatment with vedolizumab.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
30 participants (estimated)

Study arms

  • Active comparator
    Group of UC patients treated with vedolizumab

    Generic Name:vedolizumab Specification:300mg/bottle Dosage and Method of Administration:Usual adult dose for ulcerative colitis.300 mg IV every 30 minutes at weeks 0, 2, and 6, then every 8 weeks

    Drug: Vedolizumab

  • No intervention
    Normal control group

    On the basis of the exclusion criteria, there are no significant intestinal inflammatory, autoimmune or neoplastic disorders.

Interventions

  • Recommended dose in patients with UC: 300 mg intravenously at weeks 0, 2, and 6 and every 8 weeks thereafter. Discontinue vedolizumab at week 14 in patients who do not show treatment benefit.

06

What researchers measure

Primary outcomes

  1. Remission rate of patients

    Clinical remission response rates(Mayo score≤2)

    Time frame: 1 year

Secondary outcomes

  1. Baseline gut microbial composition and abundance of patients

    Macro-genome sequencing of stool samples to analyze gut microbial composition and abundance

    Time frame: 1 year

  2. Gut and serum metabolome characteristics of UC patients

    LC-MS mass spectrometry for faecal samples and serum samples to analyze metabolome characteristics

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The results can be shared

Supporting information: Study protocol

Time frame: now is available

Access criteria: All the doctors

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2021 (actual). Primary completion is estimated for Jan 2026, 60 months after the start.

Of 48 non-industry phase 4 interventional studies under Colitis, Ulcerative, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 66. This study's planned 60 months is close to that.

Counting every sponsor, half of 63 studies reached it within 43 months; a quarter within 25 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2022
First posted
Aug 1, 2022
StartActual
Jan 1, 2021
Primary completionEst.
Jan 1, 2026
CompletionEst.
Jan 1, 2026
Last update
Jul 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05481619
Responsible party
Sponsor
First posted
Aug 1, 2022
Start date
Jan 1, 2021
Primary completion
Jan 1, 2026 (estimated)
Completion
Jan 1, 2026 (estimated)
Last update
Jul 25, 2025

Study contacts

Qiao Yu, phd
Contact
yuqiao@zju.edu.cn
0086-13456820567
Yan Chen
principal investigator · 2nd Affiliated Hospital, School of Medicine, Zhejiang University, China

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vedolizumab

Start the discussion